Trastuzumab (Anti-HER2)

Trastuzumab (anti-HER2) is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2. Trastuzumab, also known as Herceptin, is a monoclonal antibody used in the treatment of HER2 positive breast cancer and other HER2 over-expressing cancers including HER2-positive metastatic cancers of the gastrointestinal tract. It works by targeting the HER2 receptor on cancer cells, which can slow or stop their growth. It can be used for synthesis of antibody-drug conjugate (ADC) by conjugate the monoclonal antibody trastuzumab with the cytotoxic drugs through a linker. For example: the FDA approved Ado-Trastuzumab emtansine (KADCYLA®) and Fam-Trastuzumab deruxtecan-nxki (ENHERTU®). This biosimilar antibody is used for research only. MW:145.53 KD.

Product Details
Species Reactivity	Human
Host/Isotype	Cell culture/ IgG1
Class	Monoclonal
Type	Antibody
Immunogen	Human Her2
Clone	Trastuzumab biosimilar
Conjugate	Unconjugated
Purity	98%
Molecular Weight	145.53 KD
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	50 mM Sodium Phosphate, 0.05% Tween-20, pH7.4